Literature DB >> 11572760

Heterogeneous breakpoints on the immunoglobulin genes are involved in fusion with the 5' region of BCL2 in B-cell tumors.

N Yonetani1, C Ueda, T Akasaka, M Nishikori, T Uchiyama, H Ohno.   

Abstract

The 5' flanking region of the BCL2 gene (5'-BCL2) is a breakpoint cluster of rearrangements with immunoglobulin genes (IGs). In contrast to t(14;18)(q32;q21) affecting the 3' region of BCL2, 5'-BCL2 can fuse to not only the heavy chain gene (IGH), but also two light chain gene (IGL) loci. We report here cloning and sequencing of a total of eleven 5'-BCL2 / IGs junctional areas of B-cell tumors, which were amplified by long-distance polymerase chain reaction-based assays. The breakpoints on 5'-BCL2 were distributed from 378 to 2312 bp upstream of the translational initiation site and, reflecting the alteration of regulatory sequences of BCL2, 5'-BCL2 / IGs-positive cells showed markedly higher levels of BCL2 expression than those of t(14;18)-positive cells. In contrast, the breakpoints on the IGs were variable. Two 5'-BCL2 / IGH and two 5'-BCL2 / IGLkappa junctions occurred 5' of the joining (J) segments, suggesting operation of an erroneous variable (V) / diversity (D) / J and V / J rearrangement mechanism. However, two other 5'-BCL2 / IGH junctions affected switch regions, and the kappa-deleting element, which is located 24 kb downstream of the constant region of IGLkappa, followed the 5'-BCL2 in another case. One 5'-BCL2 / IGLkappa and two 5'-BCL2 / IGLlambda junctions involved intronic regions where the normal recombination process does not occur. In the remaining one case, the 5'-BCL2 fused 3' of a Vlambda gene that was upstream of another Vlambda / Jlambda complex carrying a non-producing configuration, indicating that the receptor editing mechanism was likely involved in this rearrangement. Our study revealed heterogeneous anatomy of the 5'-BCL2 / IGs fusion gene leading to transcriptional activation of BCL2, and suggested that the mechanisms underlying the formation of this particular oncogene / IGs recombination are not identical to those of t(14;18).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11572760      PMCID: PMC5926849          DOI: 10.1111/j.1349-7006.2001.tb01183.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  35 in total

Review 1.  The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies.

Authors:  T G Willis; M J Dyer
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

2.  Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene.

Authors:  T Akasaka; H Akasaka; C Ueda; N Yonetani; Y Maesako; A Shimizu; H Yamabe; S Fukuhara; T Uchiyama; H Ohno
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  A variant translocation t(2;18) in follicular lymphoma involves the 5' end of bcl-2 and Ig kappa light chain gene.

Authors:  J Hillion; C Mecucci; A Aventin; D Leroux; I Wlodarska; H Van Den Berghe; C J Larsen
Journal:  Oncogene       Date:  1991-01       Impact factor: 9.867

Review 4.  Molecular insights into the immunopathogenesis of follicular lymphoma.

Authors:  K Stamatopoulos; C Kosmas; C Belessi; N Stavroyianni; P Kyriazopoulos; T Papadaki
Journal:  Immunol Today       Date:  2000-06

5.  Potential Z-DNA elements surround the breakpoints of chromosome translocation within the 5' flanking region of bcl-2 gene.

Authors:  M Adachi; Y Tsujimoto
Journal:  Oncogene       Date:  1990-11       Impact factor: 9.867

6.  V(D)J recombinase activity in a subset of germinal center B lymphocytes.

Authors:  S Han; S R Dillon; B Zheng; M Shimoda; M S Schlissel; G Kelsoe
Journal:  Science       Date:  1997-10-10       Impact factor: 47.728

7.  A conserved AU-rich element in the 3' untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis.

Authors:  N Schiavone; P Rosini; A Quattrone; M Donnini; A Lapucci; L Citti; A Bevilacqua; A Nicolin; S Capaccioli
Journal:  FASEB J       Date:  2000-01       Impact factor: 5.191

8.  Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations.

Authors:  K Offit; G Wong; D A Filippa; Y Tao; R S Chaganti
Journal:  Blood       Date:  1991-04-01       Impact factor: 22.113

9.  Refinement of the BCL2/immunoglobulin heavy chain fusion gene in t(14;18)(q32;q21) by polymerase chain reaction amplification for long targets.

Authors:  T Akasaka; H Akasaka; N Yonetani; H Ohno; H Yamabe; S Fukuhara; M Okuma
Journal:  Genes Chromosomes Cancer       Date:  1998-01       Impact factor: 5.006

10.  Molecular features of a new human lymphoma cell line carrying both BCL2 and BCL6 gene rearrangements.

Authors:  N Yonetani; T Akasaka; H Akasaka; H Ohno; M Okuma; I Miura; N Takahashi; S Miyanishi; A Okumura; M Muramatsu; S Fukuhara
Journal:  Oncogene       Date:  1998-08-27       Impact factor: 9.867

View more
  3 in total

1.  A transcriptional regulatory element in the coding sequence of the human Bcl-2 gene.

Authors:  Georgina Lang; Wendy M Gombert; Hannah J Gould
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

Review 2.  Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?

Authors:  Ricardo García-Muñoz; Luis Llorente
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

3.  Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.

Authors:  Wendi V Rodrigueza; Michael J Woolliscroft; Abdul-Shukkur Ebrahim; Robert Forgey; Patrick J McGovren; Gerold Endert; Andreas Wagner; Danielle Holewa; Amro Aboukameel; Richard D Gill; Charles L Bisgaier; Richard A Messmann; Christopher E Whitehead; Elzbieta Izbicka; Robert Streeper; Michael C Wick; Gabriela Stiegler; C A Stein; David Monsma; Craig Webb; Mina P Sooch; Steffen Panzner; Ramzi Mohammad; Neal C Goodwin; Ayad Al-Katib
Journal:  Cancer Chemother Pharmacol       Date:  2014-05-16       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.